scholarly article | Q13442814 |
P50 | author | Laurent Peyrin-Biroulet | Q30248039 |
Fernando Magro | Q37840060 | ||
Laurent Beaugerie | Q72537856 | ||
P2093 | author name string | Konstantinos H Katsanos | |
Harry Sokol | |||
Peter D Higgins | |||
Anthony Lopez | |||
Antonia Costa | |||
Elena Toader | |||
Joel C Joyce | |||
Teresa Mas de Xaxars | |||
Xavier Aldeger | |||
P2860 | cites work | Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia | Q37798607 |
P433 | issue | 1 | |
P921 | main subject | inflammation | Q101991 |
inflammatory bowel diseases | Q917447 | ||
workshop | Q27556165 | ||
P304 | page(s) | 31-44 | |
P577 | publication date | 2013-05-27 | |
P1433 | published in | Journal of Crohn's and Colitis | Q15817379 |
P1476 | title | Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). | |
P478 | volume | 8 |
Q40513902 | A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. |
Q39029698 | ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease |
Q26745782 | Advances in the development of new biologics in inflammatory bowel disease |
Q39221586 | Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives |
Q38582914 | Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management |
Q37354812 | Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes |
Q88775678 | Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease |
Q35534959 | Cancer and immunomodulators in inflammatory bowel diseases |
Q37540172 | Care of inflammatory bowel disease patients in remission |
Q26752869 | Crohn's disease and skin |
Q28085134 | Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives |
Q92759074 | Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape |
Q41293583 | Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders |
Q41990807 | European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease. |
Q50079201 | Evidence-based clinical practice guidelines for inflammatory bowel disease. |
Q28236322 | Golimumab for the treatment of ulcerative colitis |
Q33621700 | Healthcare maintenance in elderly patients with inflammatory bowel disease |
Q54299159 | Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab. |
Q28076561 | How I treat my inflammatory bowel disease-patients with thiopurines? |
Q38743666 | Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments |
Q50451653 | Incidence, management, and course of cancer in patients with inflammatory bowel disease. |
Q39773210 | Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort |
Q26823569 | Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care |
Q44262408 | Ionizing radiation exposure in patients with inflammatory bowel disease: are we overexposing our patients? |
Q59357120 | Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease |
Q38814448 | Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study |
Q40303601 | Metastatic Epstein-Barr Virus-Positive Lymphoepithelioma-Like Cholangiocarcinoma in a Young Man With Ulcerative Colitis |
Q38585910 | Monitoring for Extra-Intestinal Cancers in IBD. |
Q64259900 | Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016 |
Q38550831 | Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. |
Q39375417 | PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue |
Q57167308 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases |
Q49566489 | Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan |
Q38835478 | Practical Approaches to "Top-Down" Therapies for Crohn's Disease |
Q35193565 | Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. |
Q41726526 | Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study |
Q37439950 | Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease |
Q48249329 | Safe use of infliximab for the treatment of severe perianal Crohn's disease after diagnosis and treatment of lymphoma. |
Q38611360 | Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy. |
Q41150136 | Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. |
Q38180195 | Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. |
Q38527999 | Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. |
Q89706131 | The Complex Interplay Between Inflammatory Bowel Disease and Malignancy |
Q91856952 | The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management |
Q60017517 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease |
Q38357796 | The epidemiology of inflammatory bowel disease |
Q38237701 | The role and advances of immunomodulator therapy for inflammatory bowel disease |
Q39985219 | The safety of vedolizumab for ulcerative colitis and Crohn's disease |
Q58111244 | Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015 |
Q38977012 | Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease |
Q26750190 | Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer |
Q33621267 | Use of thiopurines in inflammatory bowel disease: Safety issues |
Q90444106 | Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience |
Q38319989 | Who and how to screen for cancer in at-risk inflammatory bowel disease patients |
Q26746994 | Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis |
Search more.